PCI 3.06.26

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Continue reading

Subsection - Oncology

Essential DMPK Strategies for IND Success

Continue reading

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Continue reading

Upcoming Events

CPHI 2027
AI in Drug Discovery
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View

Advertisement

Bachem skyscraper

Advertisement

Fujifilm

MedPharm Strengthens Executive Leadership Team with Appointment of Jason Mieding as Chief Operating Officer

MedPharm, a global leader in topical and transdermal contract drug development and manufacturing, today announced the appointment of Jason Mieding to the role of Chief Operating Officer (COO), a newly created position that reflects the growth of the organization over the past 22 months.

As COO, Jason will serve as site head for MedPharm’s state-of-the-art semisolid manufacturing facility, overseeing operational strategy, execution, and performance while contributing to strategic planning, capital allocation, organisational development, and company culture. He brings extensive experience in pharmaceutical manufacturing and operations, having held positions of increasing responsibility at Thermo Fisher Scientific and Patheon.

“I’m excited to be joining MedPharm at such an important time in the company’s history,” commented Jason Mieding, Chief Operating Officer, MedPharm. “The company has a strong reputation for its expertise and commitment to operational excellence, and I look forward to working with the team to build on this foundation, drive continuous improvement, delight our customer, and support the company’s continued growth.”

“We are delighted to welcome Jason to the team. His track record in commercial pharmaceutical manufacturing and operational excellence will be a real asset to MedPharm as our growth accelerates and we continue to invest in strengthening our capabilities,” said Bill Humphries, Chief Executive Officer, MedPharm. “His leadership will be important in supporting our team and ensuring we continue to deliver for our customers.“

About MedPharm

MedPharm is an end-to-end contract service provider of topical and transepithelial products supporting early-phase research, formulation development and in vitro testing services in addition to both clinical and commercial manufacturing. With its 2024 merger with Tergus Pharma, MedPharm enhanced its capabilities, transforming the business into a truly differentiated CDMO of scale with superior end-to-end capabilities from drug development and formulation to large batch commercial manufacturing and distribution.

For more than 25 years, MedPharm has specialised in reducing risk through its unique, industry-leading in vitro testing and research biology models and is a global leader in product development for dermal/transdermal, lung and nasal, mucosal membrane, ungual, otic and ophthalmic delivery. MedPharm has locations in the United Kingdom and the United States, including a new 110,000 sq. ft. state-of-the-art manufacturing facility in Durham, North Carolina. For more information, visit medpharm.com or follow us on LinkedIn.

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity

Advertisement

Crown Bioscience

Advertisement

Shimadzu

Advertisement

CPC